Exact Mass: 411.2773

Exact Mass Matches: 411.2773

Found 25 metabolites which its exact mass value is equals to given mass value 411.2773, within given mass tolerance error 4.0E-5 dalton. Try search metabolite list with more accurate mass tolerance error 8.0E-6 dalton.

Fesoterodine

2-[(1R)-3-[bis(propan-2-yl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl 2-methylpropanoate

C26H37NO3 (411.2773)


Fesoterodine is only found in individuals that have used or taken this drug. It is an antimuscarinic prodrug used for treating overactive bladder syndrome.Fesoterodine, once converted to its active metabolite, 5-hydroxymethyltolterodine, acts as a competitive antagonists at muscarinic receptors. This results in the inhibition of bladder contraction, decrease in detrusor pressure, and an incomplete emptying of the bladder. G - Genito urinary system and sex hormones > G04 - Urologicals > G04B - Urologicals > G04BD - Drugs for urinary frequency and incontinence C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists D000089162 - Genitourinary Agents > D064804 - Urological Agents

   

Brachystamide B

Brachystamide B

C26H37NO3 (411.2773)


   
   

SCHEMBL5850924

SCHEMBL5850924

C26H37NO3 (411.2773)


   

dysolenticin J

dysolenticin J

C26H37NO3 (411.2773)


A natural product found in Dysoxylum lenticellatum.

   

Brachystamide C|brachystamide-C|N-isobutyl-15-(3,4-methylenedioxyphenyl)-2E,4E,13E-pentadecatrienamide

Brachystamide C|brachystamide-C|N-isobutyl-15-(3,4-methylenedioxyphenyl)-2E,4E,13E-pentadecatrienamide

C26H37NO3 (411.2773)


   

(2E,4E,14E)-15-(1,3-benzodioxol-5-yl)-N-(2-methylpropyl)pentadeca-2,4,14-trienamide

NCGC00385245-01!(2E,4E,14E)-15-(1,3-benzodioxol-5-yl)-N-(2-methylpropyl)pentadeca-2,4,14-trienamide

C26H37NO3 (411.2773)


   

(2E,4E,14E)-15-(1,3-benzodioxol-5-yl)-N-(2-methylpropyl)pentadeca-2,4,14-trienamide [IIN-based on: CCMSLIB00000848860]

NCGC00385245-01!(2E,4E,14E)-15-(1,3-benzodioxol-5-yl)-N-(2-methylpropyl)pentadeca-2,4,14-trienamide [IIN-based on: CCMSLIB00000848860]

C26H37NO3 (411.2773)


   

(2E,4E,14E)-15-(1,3-benzodioxol-5-yl)-N-(2-methylpropyl)pentadeca-2,4,14-trienamide [IIN-based: Match]

NCGC00385245-01!(2E,4E,14E)-15-(1,3-benzodioxol-5-yl)-N-(2-methylpropyl)pentadeca-2,4,14-trienamide [IIN-based: Match]

C26H37NO3 (411.2773)


   

Fesoterodine

2-[(1R)-3-[bis(propan-2-yl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl 2-methylpropanoate

C26H37NO3 (411.2773)


G - Genito urinary system and sex hormones > G04 - Urologicals > G04B - Urologicals > G04BD - Drugs for urinary frequency and incontinence C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists D000089162 - Genitourinary Agents > D064804 - Urological Agents

   

NA 26:8;O

(5E,7E)-8-[(3aS,4R,5R,7aR)-4-[(1Z,3E)-5-oxo-5-(isobutylamino)-penta-1,3-dienyl]-2,3,3a,4,5,7a-hexahydro-1H-inden-5-yl]octa-5,7-dienoic acid

C26H37NO3 (411.2773)


   

1-[12-(4-ethylphenyl)dodecoxy]-2-nitrobenzene

1-[12-(4-ethylphenyl)dodecoxy]-2-nitrobenzene

C26H37NO3 (411.2773)


   

Fesoterodine maleate

Fesoterodine maleate

C26H37NO3 (411.2773)


   

NA-Dopamine 18:4(6Z,9Z,12Z,15Z)

NA-Dopamine 18:4(6Z,9Z,12Z,15Z)

C26H37NO3 (411.2773)


   

15-(2h-1,3-benzodioxol-5-yl)-n-(2-methylpropyl)pentadeca-2,4,14-trienimidic acid

15-(2h-1,3-benzodioxol-5-yl)-n-(2-methylpropyl)pentadeca-2,4,14-trienimidic acid

C26H37NO3 (411.2773)


   

(1s,3r,6r,7z,9e,13s,15r,16r)-13-methoxy-3,15-dimethyl-6-[(2s,3z)-6-methylhepta-3,5-dien-2-yl]-12-azatetracyclo[8.5.1.0³,⁷.0¹³,¹⁶]hexadeca-7,9,11-triene-11,15-diol

(1s,3r,6r,7z,9e,13s,15r,16r)-13-methoxy-3,15-dimethyl-6-[(2s,3z)-6-methylhepta-3,5-dien-2-yl]-12-azatetracyclo[8.5.1.0³,⁷.0¹³,¹⁶]hexadeca-7,9,11-triene-11,15-diol

C26H37NO3 (411.2773)


   

(2e,4e,12e)-15-(2h-1,3-benzodioxol-5-yl)-n-[(2s)-butan-2-yl]pentadeca-2,4,12-trienimidic acid

(2e,4e,12e)-15-(2h-1,3-benzodioxol-5-yl)-n-[(2s)-butan-2-yl]pentadeca-2,4,12-trienimidic acid

C26H37NO3 (411.2773)


   

15-(2h-1,3-benzodioxol-5-yl)-n-(2-methylpropyl)pentadeca-2,4,13-trienimidic acid

15-(2h-1,3-benzodioxol-5-yl)-n-(2-methylpropyl)pentadeca-2,4,13-trienimidic acid

C26H37NO3 (411.2773)


   

3-[(1r,3as,5as,7r,9ar,9br,11as)-7-hydroxy-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,5h,5ah,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]-5-hydroxypyrrol-2-one

3-[(1r,3as,5as,7r,9ar,9br,11as)-7-hydroxy-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,5h,5ah,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]-5-hydroxypyrrol-2-one

C26H37NO3 (411.2773)


   

(2e,4e,13e)-15-(2h-1,3-benzodioxol-5-yl)-n-(2-methylpropyl)pentadeca-2,4,13-trienimidic acid

(2e,4e,13e)-15-(2h-1,3-benzodioxol-5-yl)-n-(2-methylpropyl)pentadeca-2,4,13-trienimidic acid

C26H37NO3 (411.2773)


   

(2e,4e,14e)-15-(2h-1,3-benzodioxol-5-yl)-n-[(2s)-butan-2-yl]pentadeca-2,4,14-trienimidic acid

(2e,4e,14e)-15-(2h-1,3-benzodioxol-5-yl)-n-[(2s)-butan-2-yl]pentadeca-2,4,14-trienimidic acid

C26H37NO3 (411.2773)


   

(2e,4e,12e)-15-(2h-1,3-benzodioxol-5-yl)-n-(2-methylpropyl)pentadeca-2,4,12-trienimidic acid

(2e,4e,12e)-15-(2h-1,3-benzodioxol-5-yl)-n-(2-methylpropyl)pentadeca-2,4,12-trienimidic acid

C26H37NO3 (411.2773)


   

(2e,4e,14e)-15-(2h-1,3-benzodioxol-5-yl)-n-(2-methylpropyl)pentadeca-2,4,14-trienimidic acid

(2e,4e,14e)-15-(2h-1,3-benzodioxol-5-yl)-n-(2-methylpropyl)pentadeca-2,4,14-trienimidic acid

C26H37NO3 (411.2773)


   

15-hydroxy-13-methoxy-3,15-dimethyl-6-(6-methylhepta-3,5-dien-2-yl)-12-azatetracyclo[8.5.1.0³,⁷.0¹³,¹⁶]hexadeca-7,9-dien-11-one

15-hydroxy-13-methoxy-3,15-dimethyl-6-(6-methylhepta-3,5-dien-2-yl)-12-azatetracyclo[8.5.1.0³,⁷.0¹³,¹⁶]hexadeca-7,9-dien-11-one

C26H37NO3 (411.2773)


   

15-(2h-1,3-benzodioxol-5-yl)-n-(2-methylpropyl)pentadeca-2,4,12-trienimidic acid

15-(2h-1,3-benzodioxol-5-yl)-n-(2-methylpropyl)pentadeca-2,4,12-trienimidic acid

C26H37NO3 (411.2773)